Disease-specific alterations in frontal cortex brain proteins in schizophrenia, bipolar disorder, and major depressive disorder
The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Severe psychiatric disorders such as schizophrenia, bipolar disorder and major depressive disorder are brain diseases of unknown origin. No biological marker has been documented at the pathological, cellular, or molecular level, suggesting that a number of complex but subtle changes underlie these illnesses. We have used proteomic technology to survey postmortem tissue to identify changes linked to the various diseases. Proteomics uses two-dimensional gel electrophoresis and mass spectrometric sequencing of proteins to allow the comparison of subsets of expressed proteins among a large number of samples. This form of analysis was combined with a multivariate statistical model to study changes in protein levels in 89 frontal cortices obtained postmortem from individuals with schizophrenia, bipolar disorder, major depressive disorder, and non-psychiatric controls. We identified eight protein species that display disease-specific alterations in level in the frontal cortex. Six show decreases compared with the non-psychiatric controls for one or more diseases. Four of these are forms of glial fibrillary acidic protein (GFAP), one is dihydropyrimidinase-related protein 2, and the sixth is ubiquinone cytochrome c reductase core protein 1. Two spots, carbonic anhydrase 1 and fructose biphosphate aldolase C, show increase in one or more diseases compared to controls. Proteomic analysis may identify novel pathogenic mechanisms of human neuropsychiatric diseases.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Most of these used glial fibrillary acidic protein (GFAP) as a marker for astrocytes, and reported that GFAP, or GFAPpositive cells were decreased in mood-disordered subjects relative to controls (Johnston-Wilson et al, 2000;Si et al, 2004;Rajkowska and Miguel-Hidalgo, 2007).”
From Neurocircuitry of Mood Disorders (2010) · cites this paper as Johnston-Wilson et al, 2000
In the citing paper
“In the frontal cortex one study found that four forms of the astrocytic product, glial fibrillary acidic protein (GFAP), were decreased in mood-disordered subjects relative to controls, although it was not determined whether this decrement reflected a reduction in the astrocyte density or the GFAP expression (Johnston-Wilson et al. 2000).”
From Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression (2008) · cites this paper as Johnston-Wilson et al. 2000
Citations
Cites
High resolution two-dimensional electrophoresis of proteins.
O'Farrell, P. (1975) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)41496-8 · Cited by 19,246
Shevchenko, A., Jensen, O. N., Podtelejnikov, A. V., Sagliocco, F., Wilm, M., Vorm, O., Mortensen, P., Shevchenko, A., Boucherie, H., & Mann, M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.25.14440 · Cited by 1,427
Eng, L. F., & Ghirnikar, R. S. (1994) · Brain Pathology · doi:10.1111/j.1750-3639.1994.tb00838.x · Cited by 864
Collapsin-induced growth cone collapse mediated by an intracellular protein related to UNC-33
Goshima, Y., Nakamura, F., Strittmatter, P., & Strittmatter, S. M. (1995) · Nature · doi:10.1038/376509a0 · Cited by 706
Quantitative aspects of reactive gliosis: A review
Norton, W. T., Aquino, D. A., Hozumi, I., Chiu, F. C., & Brosnan, C. F. (1992) · Neurochemical Research · doi:10.1007/bf00993263 · Cited by 549
Modulation of pH by neuronal activity
Chesler, M., & Kaila, K. (1992) · Trends in Neurosciences · doi:10.1016/0166-2236(92)90191-a · Cited by 531
A Family of Rat CRMP Genes Is Differentially Expressed in the Nervous System
Wang, L.-H., & Strittmatter, S. M. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-19-06197.1996 · Cited by 347
A CYTOCHEMICAL STUDY OF THE LOCALIZATION OF CARBONIC ANHYDRASE IN THE NERVOUS SYSTEM
Giacobini, E. (1962) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1962.tb11859.x · Cited by 235
Hamajima, N., Matsuda, K., Sakata, S., Tamaki, N., Sasaki, M., & Nonaka, M. (1996) · Gene · doi:10.1016/s0378-1119(96)00445-3 · Cited by 208
Perrone-Bizzozero, N. I., Sower, A. C., Bird, E. D., Benowitz, L. I., Ivins, K. J., & Neve, R. L. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.24.14182 · Cited by 206
Cited by
Drevets, W. C., Price, J. L., & Furey, M. L. (2008) · Brain Structure and Function · doi:10.1007/s00429-008-0189-x · Cited by 2,241
“…four forms of the astrocytic product, glial fibrillary acidic protein (GFAP), were decreased in mood-disordered subjects relative to controls, although it was not determined whether this decrement reflected a reduction in the astrocyte density or the GFAP expression (Johnston-Wilson et al. 2000).”
BackgroundNeurocircuitry of Mood Disorders
Price, J. L., & Drevets, W. C. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.104 · Cited by 1,606
Middeldorp, J., & Hol, E. M. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.01.005 · Cited by 1,080
The tripartite synapse: roles for gliotransmission in health and disease
Halassa, M. M., Fellin, T., & Haydon, P. G. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.12.005 · Cited by 852
Epigenomic Profiling Reveals DNA-Methylation Changes Associated with Major Psychosis
Mill, J., Tang, T., Kaminsky, Z., Khare, T., Yazdanpanah, S., Bouchard, L., Jia, P., Assadzadeh, A., Flanagan, J., Schumacher, A., et al. (2008) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2008.01.008 · Cited by 773
Cotter, D., Mackay, D., Landau, S., Kerwin, R., & Everall, I. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.6.545 · Cited by 766
Neuroinflammation and psychiatric illness
Najjar, S., Pearlman, D. M., Alper, K., Najjar, A., & Devinsky, O. (2013) · Journal of Neuroinflammation · doi:10.1186/1742-2094-10-43 · Cited by 733
“Density Decreased (highly reproducible) [35-41]; few exceptions [42,43] Reduced or no change [37,44-46] Reduced or no change [37-39,47-49] [42,50,51] Insufficient data”
InfluentialThe immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression
Müller, N., & Schwarz, M. J. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4002006 · Cited by 670
Uranova, N. A., Vostrikov, V. M., Orlovskaya, D. D., & Rachmanova, V. I. (2004) · Schizophrenia Research · doi:10.1016/s0920-9964(03)00181-6 · Cited by 659
Cotter, D. (2002) · Cerebral Cortex · doi:10.1093/cercor/12.4.386 · Cited by 634
Gliogenesis and Glial Pathology in Depression
Rajkowska, G., & Miguel-Hidalgo, J. (2007) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152707780619326 · Cited by 610
Astrocyte Pathology in Major Depressive Disorder: Insights from Human Postmortem Brain Tissue
Rajkowska, G., & Stockmeier, C. (2013) · Current Drug Targets · doi:10.2174/13894501113149990156 · Cited by 603
Glial Loss in the Prefrontal Cortex Is Sufficient to Induce Depressive-like Behaviors
Banasr, M., & Duman, R. S. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.06.008 · Cited by 602
Glial cell abnormalities in major psychiatric disorders: the evidence and implications
Cotter, D. R., Pariante, C. M., & Everall, I. P. (2001) · Brain Research Bulletin · doi:10.1016/s0361-9230(01)00527-5 · Cited by 465
Orbitofrontal cortex function and structure in depression
DREVETS, W. C. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1401.029 · Cited by 417
Glial reduction in amygdala in major depressive disorder is due to oligodendrocytes
Hamidi, M., Drevets, W. C., & Price, J. L. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2003.11.006 · Cited by 369
Mitochondria and Mood: Mitochondrial Dysfunction as a Key Player in the Manifestation of Depression
Allen, J., Romay-Tallon, R., Brymer, K. J., Caruncho, H. J., & Kalynchuk, L. E. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00386 · Cited by 347
WANG, J., CHEN, C., LIU, Y., JIAO, F., LI, W., LAO, F., LI, Y., LI, B., GE, C., & ZHOU, G. (2008) · Toxicology Letters · doi:10.1016/j.toxlet.2008.10.001 · Cited by 337
Evaluating historical candidate genes for schizophrenia
Farrell, M. S., Werge, T., Sklar, P., Owen, M. J., Ophoff, R. A., O'Donovan, M. C., Corvin, A., Cichon, S., & Sullivan, P. F. (2015) · Molecular Psychiatry · doi:10.1038/mp.2015.16 · Cited by 315
The neuropathology of primary mood disorder
Harrison, P. J. (2002) · Brain · doi:10.1093/brain/awf149 · Cited by 322
Serum S100B and antioxidant enzymes in bipolar patients
Andreazza, A. C., Cassini, C., Rosa, A. R., Leite, M. C., de Almeida, L. M. V., Nardin, P., Cunha, A. B. N., Ceresér, K. M., Santin, A., Gottfried, C., et al. (2007) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2006.07.013 · Cited by 309
Apoptotic mechanisms and the synaptic pathology of schizophrenia
Glantz, L. A., Gilmore, J. H., Lieberman, J. A., & Jarskog, L. F. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2005.08.014 · Cited by 292
Microarray analysis of postmortem temporal cortex from patients with schizophrenia
Aston, C., Jiang, L., & Sokolov, B. P. (2004) · Journal of Neuroscience Research · doi:10.1002/jnr.20208 · Cited by 283
Si, X., Miguel-Hidalgo, J. J., O'Dwyer, G., Stockmeier, C. A., & Rajkowska, G. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300525 · Cited by 268
Charrier, E., Reibel, S., Rogemond, V., Aguera, M., Thomasset, N., & Honnorat, J. (2003) · Molecular Neurobiology · doi:10.1385/mn:28:1:51 · Cited by 266
Beasley, C. L., Pennington, K., Behan, A., Wait, R., Dunn, M. J., & Cotter, D. (2006) · PROTEOMICS · doi:10.1002/pmic.200500069 · Cited by 263
Human astrocytes in the diseased brain
Dossi, E., Vasile, F., & Rouach, N. (2018) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2017.02.001 · Cited by 250
Najjar, S., Pearlman, D. M., Devinsky, O., Najjar, A., & Zagzag, D. (2013) · Journal of Neuroinflammation · doi:10.1186/1742-2094-10-142 · Cited by 248
“Astroglial loss ● [20,21,126-133] ● [134-138] ● [139-141]”
Tabarés-Seisdedos, R., & Rubenstein, J. L. R. (2009) · Molecular Psychiatry · doi:10.1038/mp.2009.2 · Cited by 244
Sanacora, G., & Banasr, M. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.03.032 · Cited by 239
Pennington, K., Beasley, C. L., Dicker, P., Fagan, A., English, J., Pariante, C. M., Wait, R., Dunn, M. J., & Cotter, D. R. (2008) · Molecular Psychiatry · doi:10.1038/sj.mp.4002098 · Cited by 227
Ogden, C. A., Rich, M. E., Schork, N. J., Paulus, M. P., Geyer, M. A., Lohr, J. B., Kuczenski, R., & Niculescu, A. B. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001547 · Cited by 221
Glial and glutamatergic markers in depression, alcoholism, and their comorbidity
Miguel-Hidalgo, J. J., Waltzer, R., Whittom, A. A., Austin, M. C., Rajkowska, G., & Stockmeier, C. A. (2010) · Journal of Affective Disorders · doi:10.1016/j.jad.2010.06.003 · Cited by 218
“The levels of GFAP or its mRNA, and the spatial extent occupied by GFAP immunoreactive processes were reduced in the PFC in depression (Johnston-Wilson et al., 2000; MiguelHidalgo et al., 2000; Si et al., 2004) (although in late-life depression there might be a rebound increase in GFAP levels…”
BackgroundCoverage of Blood Vessels by Astrocytic Endfeet Is Reduced in Major Depressive Disorder
Rajkowska, G., Hughes, J., Stockmeier, C. A., Javier Miguel-Hidalgo, J., & Maciag, D. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.09.024 · Cited by 209
Webster, M. J., Knable, M. B., Johnston-Wilson, N., Nagata, K., Inagaki, M., & Yolken, R. H. (2001) · Brain, Behavior, and Immunity · doi:10.1006/brbi.2001.0646 · Cited by 179
Self-citationThe role of oligodendrocyte pathology in schizophrenia
Uranova, N. A., Vostrikov, V. M., Vikhreva, O. V., Zimina, I. S., Kolomeets, N. S., & Orlovskaya, D. D. (2007) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145707007626 · Cited by 176
Zuccoli, G. S., Saia-Cereda, V. M., Nascimento, J. M., & Martins-de-Souza, D. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00493 · Cited by 157
Serum markers support disease-specific glial pathology in major depression
Schroeter, M. L., Abdul-Khaliq, H., Krebs, M., Diefenbacher, A., & Blasig, I. E. (2008) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.03.005 · Cited by 152
Towards understanding the schizophrenia code: an expanded convergent functional genomics approach
Le‐Niculescu, H., Balaraman, Y., Patel, S., Tan, J., Sidhu, K., Jerome, R. E., Edenberg, H. J., Kuczenski, R., Geyer, M. A., Nurnberger, J. I., et al. (2007) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30481 · Cited by 137
Martins-de-Souza, D., Harris, L. W., Guest, P. C., & Bahn, S. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3459 · Cited by 134
Proteomic analysis of glial fibrillary acidic protein in Alzheimer's disease and aging brain
Korolainen, M. A., Auriola, S., Nyman, T. A., Alafuzoff, I., & Pirttilä, T. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.05.021 · Cited by 133
Föcking, M., Dicker, P., English, J. A., Schubert, K. O., Dunn, M. J., & Cotter, D. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.43 · Cited by 90
How do glial-neuronal interactions fit into current neurotransmitter hypotheses of schizophrenia?
Kondziella, D., Brenner, E., Eyjolfsson, E. M., & Sonnewald, U. (2007) · Neurochemistry International · doi:10.1016/j.neuint.2006.09.006 · Cited by 83
Cellular abnormalities in depression: evidence from postmortem brain tissue
Stockmeier, C. A., & Rajkowska, G. (2004) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2004.6.2/cstockmeier · Cited by 67
Tissue preparation and banking
Webster, M. J. (2006) · Progress in Brain Research · doi:10.1016/s0079-6123(06)58001-x · Cited by 67
Kahl, K. G., Stapel, B., & Frieling, H. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.09.004 · Cited by 47
Psychiatric phenotypes in chronic traumatic encephalopathy
Mahar, I., Alosco, M. L., & McKee, A. C. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.08.023 · Cited by 36
“The frontal cortex has also been implicated in depression, suicide, and other psychiatric conditions (Frey et al., 2007; Goswami et al., 2013; Johnston-Wilson et al., 2000; Schneider et al., 2015; Sequeira et al., 2009; Taylor et al., 2014).”
Neuroimaging and Neuropathological Studies of Mood Disorders
Drevets, W. C., & Price, J. L. (2005) · Biology of Depression · doi:10.1002/9783527619672.ch17 · Cited by 26
Rajkowska, G., & Miguel-Hidalgo, J. J. (2019) · Methods in Molecular Biology · doi:10.1007/978-1-4939-9068-9_17 · Cited by 18
Metadata
- Authors
- Johnston-Wilson, N. L., Sims, C. D., Hofmann, J.-P., Anderson, L., Shore, A. D., Torrey, E. F., Yolken, R. H., & the Stanley Neuropathology Consortium
- Affiliations
- Johns Hopkins University (US)
- Corresponding author
- Johnston-Wilson, N L
- ORCID
- Shore, A D
- Venue
- Molecular Psychiatry
- Published
- 2000-03-01
- Volume
- 5
- Issue
- 2
- Pages
- 142-149
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- OpenAlex
- W2328048826
- Cited by
- 531
- References
- 45
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 17 · 2023: 14 · 2022: 12 · 2021: 27 · 2020: 19 · 2019: 14 · 2018: 22 · 2017: 16 · 2016: 29 · 2015: 27 · 2014: 29 · 2013: 22 · 2012: 27
- FWCI
- 9.79
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Molecular Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Physical Sciences › Chemistry › Spectroscopy › Advanced Proteomics Techniques and Applications
- Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
- Keywords
- schizophrenia, bipolar disorder, major depressive disorder, frontal cortex, brain proteins, postmortem brain, proteomics, glial fibrillary acidic protein, carbonic anhydrase I, biomarkers
- MeSH terms
- Collapsin Response Mediator Protein 1, Amino Acid Sequence, Autopsy, Bipolar Disorder, Carbonic Anhydrases, Depressive Disorder, Frontal Lobe, Fructose-Bisphosphate Aldolase, Glial Fibrillary Acidic Protein, Humans, Image Processing, Computer-Assisted, Molecular Sequence Data, Nerve Tissue Proteins, Peptide Fragments, Reference Values, Schizophrenia, Electron Transport Complex III, Electrophoresis, Gel, Two-Dimensional
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.